Vivus (NASDAQ:VVUS), a company whose shares are moving quickly, is trading 1.5% lower to $11.34. The Dow Jones Industrial Average is now trading 0.4% lower to 14,804 and the S&P is trading 0.8% lower to 1,581.
VIVUS, Inc. develops and manufactures therapies for the treatment of men with erectile dysfunction. The Company is currently marketing MUSE and ACTIS in the United States and has license agreements with other companies to market its products internationally. VIVUS is also conducting clinical trials for another treatment.
Potential upside of 54.3% exists for Vivus, based on a current level of $11.34 and analysts' average consensus price target of $17.50. The stock should run into initial resistance at its 50-day moving average (MA) of $11.68 and subsequent resistance at its 200-day MA of $16.83.
In the past 52 weeks, shares of Vivus have traded between a low of $9.86 and a high of $31.21 and are now at $11.34, which is 15% above that low price. Over the past week, the 200-day moving average (MA) has gone down 1.8% while the 50-day MA has declined 1%.